The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease.

Trial Profile

The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Aspirin-treated Subjects With Stable Coronary Artery Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Prasugrel (Primary) ; Aspirin; Clopidogrel
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms PARADOX
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 09 Nov 2011 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top